Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks


Liquid Biopsies, a Game Changer

Liquid biopsies, enabled by ultrasensitive PCR and next generation sequencing technologies, allow for a less invasive way to detect cancer, monitor response to treatment, and support patient stratification for targeted therapies. In this session the leaders who are working to make liquid biopsies standardized in the oncology clinic will discuss their advances in developing key molecular signatures that can be detected in blood and urine, the roles of cell free DNA and circulating tumor cells in their work, and how treatment for patients with lung, breast, ovarian, bladder, and other cancers will benefit.


Frederic Pla, Ph.D., Chief Business & Product Development Officer, Genomic Health

Over the last 25 years, Frederic Pla has built and launched global businesses in medical diagnostics and devices, life sciences, and healthcare information technology, consistently delivering high growth and profitability through a blend of product innovation, strategic acquisitions, and successful turnarounds.  Read Full Bio

Thomas Krahn, Ph.D., Head of Global Biomarker Research, Bayer Pharmaceuticals

Dr. Thomas Krahn is heading the department of Global Biomarker Research within Bayer Pharma AG. The main task of this department is translational research supporting early clinical trials by identification and qualification of specific biomarkers and evaluation of new technologies. Read Full Bio

Wolfgang Daum, Chairman and CEO, Toma Biosciences

Wolfgang is an executive and serial entrepreneur in healthcare (diagnostics, medical devices, and health services). Currently he serves as Chairman and CEO of TOMA Biosciences, Inc., a fast growing genomic cancer diagnostic company. Read Full Bio 

Nicholas Dracopoli, Ph.D., Vice President, Janssen R&D

Dr. Nicholas Dracopoli is Vice President, Head Oncology Biomarkers at Janssen R&D, Johnson & Johnson. In this role he is responsible for biomarker discovery, development and applications for oncology products. Read Full Bio 

Matthew Hill, Ph.D., Vice President, Research & Development, Natera

Dr. Hill is an expert in genetics, molecular biology, and bioinformatics. While in graduate school at Stanford, Dr. Hill constructed the first genetic map of a chordate model organism which led to important insights about the nature of genome evolution. Read Full Bio 

Raghu Kalluri, M.D., Ph.D., Chairman & Professor, Dept. of Cancer Biology, MD Anderson

In 2015, Kalluri’s lab at MD Anderson received widespread attention for a discovery that could lead to a blood test that detects pancreatic cancer at an early stage, before it spreads to other organs and becomes too difficult to treat. Kalluri received his PhD in Biochemistry and Molecular Biology from the University of Kansas Medical Center and his M.D. degree from Brown University Medical School. Read Full Bio

Katherine Richardson, Ph.D., Vice President, Research and Development, Transgenomic, Inc

Dr. Richardson holds an SB degree in Life Sciences from the Massachusetts Institute of Technology and a PhD in Molecular Cellular and Developmental Biology from Iowa State University. Prior to joining Transgenomic, she worked for eight years as a scientist with OSI Pharmaceuticals, where she specialized in molecular biology research and development in the area of oncology. Read Full Bio

George Karlin-Neumann, Ph.D., Director of Scientific Affairs, Bio-Rad

Dr. George Karlin-Neumann is a molecular geneticist, biotechnologist and entrepreneur. He co-founded ParAllele BioScience, a successful high throughput genomics company, out of the Stanford Genome Technology Center in 2001. Dr.Karlin-Neumann joined Affymetrix in 2005 after it acquired ParAllele for its highly multiplexed genetics and genomics assay technology. Read Full Bio

Web Analytics